

Published in final edited form as:

Angew Chem Int Ed Engl. 2014 June 10; 53(24): 6206–6210. doi:10.1002/anie.201402571.

Enantioselective Total Synthesis of (–)-Lansai B and (+)-Nocardioazines A and B **

Haoxuan Wang and Prof. Sarah E. Reisman*

Warren and Katharine Schlinger Laboratory of Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125 (USA)

Abstract

The concise total syntheses of the bis(pyrroloindolines) (–)-lansai B and (+)- nocardioazines A and B are reported. The key pyrroloindoline building blocks are rapidly prepared by enantioselective formal (3 + 2) cycloaddition reactions. The macrocycle of (+)-nocardioazine A is constructed by an unusual intramolecular diketopiperazine formation.

Keywords

lansai B; nocardioazines; natural products; total synthesis; diketopiperazine synthesis

Pyrroloindoline natural products are a growing family of alkaloids that exhibit promising biological properties, including antibacterial and anticancer activities.¹ Within this family, a number of bis(pyrroloindolines) that are joined through a central diketopiperazine (DKP) ring have been identified.² These structures include (–)-lansai B (**1**), (+)-nocardioazine A (**2**), and (+)- nocardioazine B (**3**). Nocardioazine A (**2**) is of particular interest due to its activity as an inhibitor of P-glycoprotein, a transmembrane protein overexpressed in many multi-drug resistant tumors.^{2b} Although these natural products appear quite similar structurally, close analysis reveals subtle differences in the relative stereochemistry of the pyrroloindoline units. Whereas **1** is composed of two *exo*-pyrroloindolines, **2** and **3** each possess one *endo*- and one *exo*-pyrroloindoline. Moreover, the *endo*- and *exo*-pyrroloindolines are in the opposite enantiomeric series, which is necessary to geometrically accommodate the macrocycle of **2**. This interesting stereochemical relationship makes **2** and **3** appealing synthetic targets for asymmetric catalysis, where selection of the appropriate enantiomer of catalyst dictates the absolute stereochemistry of the pyrroloindoline building

** We thank Prof. Brian Stoltz, Dr. Scott Virgil, and the Caltech Center for Catalysis and Chemical Synthesis for access to analytical equipment, as well as Materia, Inc. and Sigma-Aldrich for kind donations of chemicals. We are grateful to Dr. David VanderVelde for assistance with NMR structure analysis, and Mr. Larry Henling for X-ray structure determination. The Bruker KAPPA APEXII X-ray diffractometer was purchased via an NSF Chemistry Research Instrumentation award to Caltech (CHE-0639094). NMR spectra were obtained on a spectrometer funded by the NIH (RR027690). S.E.R. is a fellow of the Alfred P. Sloan Foundation, a Camille Dreyfus Teacher-Scholar, and an American Cancer Society Research Scholar. Financial support from the California Institute of Technology, the NIH (NIGMS RGM097582A), and DuPont is gratefully acknowledged.

© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

*reisman@caltech.edu, Homepage: <http://reismangroup.caltech.edu>.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.2014xxxxx>.

block. The first diastereoselective total synthesis of **3** was reported in 2012 by the Ye group and required 10 steps starting from L- and D-tryptophan;³ no total syntheses of **1** or **2** have been published to date.

Recently, we reported a new method to prepare enantioenriched pyrroloindolines from C3-substituted indoles and 2-amidoacrylates using SnCl₄ and catalytic (*R*)-3,3'-dichloro-BINOL (Figure 1).⁴ Based on the retrosynthetic analysis shown in Figure 1, we anticipated that this formal (3 + 2) cycloaddition reaction could be used to rapidly and enantioselectively prepare natural products **1**, **2** and **3**. Herein, we report the successful execution of this plan and demonstrate the utility of this catalytic asymmetric method for the synthesis of diketopiperazine-containing bis(pyrroloindolines).

We first targeted (–)-lansai B (**1**, Figure 1); retrosynthetically, it was envisioned that the DKP core could be prepared from the union of pyrroloindolines *exo*-**4** and *exo*-**5** via sequential peptide bond formation. The required pyrroloindolines could in turn be synthesized by formal (3 + 2) cycloaddition reactions of the corresponding indoles **13** and **16** (Scheme 1).

Our efforts commenced with Suzuki-Miyaura coupling of bromoindole **11**^{4a} and prenylboronate **12** to furnish reverse-prenylated indole **13** in good yield.⁵ Subjection of indole **13** and methyl 2-trifluoroacetamidoacrylate (**9a**) to our formal (3 + 2) cycloaddition conditions on 0.2 mmol scale provided pyrroloindoline **14** in 84% yield and 92% ee. However, lower yields of **14** were obtained when the reaction was conducted on preparatively useful scales (>1.0 mmol). It was hypothesized that on small scale trace water might help to turn over the chiral catalyst; a survey of several protic additives revealed that addition of 0.4 equiv 2,6-dibromophenol to the reaction mixture improves the scalability of the reaction, providing **14** in 85% yield, 14:1 dr, and 92 % ee (major diastereomer). Presumably 2,6-dibromophenol facilitates turnover of the chiral catalyst, but is not reactive enough to protonate the transient enolate directly in a non-selective fashion. Cleavage of the TFA group with anhydrous HCl provided amine **15**.⁶ Likewise, pyrroloindoline **17** could be prepared from 1,3-dimethyl indole **16** and acrylate **9a** in 79% yield, 12:1 dr, and 93% ee (major diastereomer). Treatment with LiOH chemoselectively hydrolyzed the methyl ester to give carboxylic acid **18**.

With orthogonally-protected pyrroloindolines **15** and **18** in hand, completion of the synthesis required DKP formation. Unfortunately, amide **19** was not formed under a wide variety of peptide coupling conditions (Scheme 1);⁷ instead, decomposition of acid **18** was observed. We note that Danishefsky and coworkers successfully couple two orthogonally-protected *exo*-pyrroloindolines in their synthesis of amaumine; however, in contrast to **18**, the carboxylic acid partner in the Danishefsky system contained electron-withdrawing *t*-butylcarbamate protecting groups on both nitrogen atoms.⁸ Taken together, these findings reveal that the *N*-substitution of the *exo*-pyrroloindoline significantly influences the stability of the activated ester under peptide coupling conditions. After considerable experimentation, it was determined that pyrroloindolines **17** and **14** could be converted to amino acids **20** and **21** by TFA deprotection and saponification (Scheme 2). Although we recognized that use of the amino acids in the coupling reaction could give rise to a mixture of three possible

diketopiperazines (the desired heterodimer and two homodimers), we reasoned that the overall process could still be more efficient than proceeding through a series of protecting group manipulations. Thus, treatment of an equimolar mixture of amino acids **20** and **21** with BOP-Cl delivered (–)-lansai B (**1**) in 38% yield. Each of the two homodimers was also isolated in 20% yield.⁹ Despite the modest yield on the final coupling step, the natural product is accessible in only six steps (longest linear sequence) and 20% overall yield from commercially available materials.

Having completed the synthesis of **1**, we turned our attention to the synthesis of nocardioazines A (**2**) and B (**3**). Retrosynthetically, it was envisioned that both **2** and **3** could be accessed from the DKP generated by coupling pyrroloindolines *endo*-**6** and *exo*-**7** (Figure 1). In the forward sense, treatment of a solution of *N*-methyl-3-allyl indole (**22**) and acrylate **9a** with (*S*)-BINOL (20 mol %) and SnCl₄ (1.6 equiv) delivered *exo*-pyrroloindoline **23** in 52% yield and 90% ee (Scheme 3). These conditions were highly diastereoselective for *exo*-**23** (19:1); however, the yield is modest due to allyl migration from C3 to C2 of the indole under the reaction conditions.⁹ Neither addition of 2,6-dibromophenol nor use of other catalysts improved the yield of **23**. Cleavage of the TFA group using TfOH in anhydrous methanol provided, upon basic workup, *exo*-amine **24**.

On the other hand, treatment of *N*-allylindole **25** and benzyl trifluoroacetamidoacrylate (**9b**) with (*R*)-3,3'-dichloro-BINOL (20 mol %), SnCl₄ (1.6 equiv) and 2,6-dibromophenol (0.4 equiv) furnished *exo*-pyrroloindoline **26** in 57% yield and 98% ee (Scheme 3). The modest yield of *exo*-**26** results from the moderate diastereoselectivity (5.8:1) of the transformation. Following transesterification, epimerization using LiHMDS followed by cleavage of the methyl ester with BBr₃ delivered *endo*-pyrroloindoline **27**.

With access to *endo*-acid **27** and *exo*-amine **24**, we were poised to prepare key DKP **29** (Scheme 3). In contrast to our unsuccessful efforts to couple *exo*-pyrroloindolines **15** and **18**, it was determined that slow addition of acid **27** to 2.0 equiv amine **24** and BOP-Cl provides **28** in 84% yield.¹⁰ Importantly, the unreacted amine **24** was recovered by silica gel chromatography. When compared to the challenges encountered in the coupling of *exo*-pyrroloindolines **15** and **18**, the ability to couple *exo*-**24** and *endo*-**27** reveals that, in addition to the identity of the *N*-substituents, the relative stereochemistry of the pyrroloindoline coupling partners is determinate of the ease of peptide formation. Saponification of **28** with LiOH followed by acidification with 1M HCl delivered DKP **29**. Subsequent Pd-catalyzed deallylation of **29** gave amine **30**,¹¹ which upon cross metathesis with 2-methyl-2-butene¹² provided (+)- nocardioazine B (**3**). Thus, the enantioselective total synthesis of (+)-**3** was completed in nine linear steps and 21% overall yield from 3-methylindole.

At this stage, our focus shifted to advancing amine **30** to (+)- nocardioazine A (**2**). Cross metathesis of **30** with excess methacrolein delivered enal **31** in 76% yield as a 10:1 *E/Z* mixture (Scheme 4). Luche reduction followed by Finkelstein chlorination provided allyl chloride **33**. Gratifyingly, treatment of **33** with TBAI and base in acetonitrile at 80 °C promoted intramolecular *N*-alkylation, furnishing macrocycle **34**. Unfortunately, exposure of **34** to a wide variety of epoxidation conditions, including dimethyldioxirane, *m*-chloroperbenzoic acid, and Jacobsen epoxidation catalysts, failed to produce the natural

product; instead, the major product was unstable *N*-oxide **35**. Use of excess oxidant or efforts to isolate **35** and resubject it to epoxidation conditions were also unfruitful, indicating that the trisubstituted alkenes of **34** and **35** are remarkably inert toward epoxidation. Inspection of the crystal structure of alkene **34** suggests that the poor reactivity does not simply result from steric shielding of the double bond; instead, the electron-withdrawing allylic nitrogen might inductively deactivate the alkene toward electrophiles.

Alternatively, it was possible to diastereoselectively dihydroxylate alkene **34** using potassium osmate.¹³ Selective mesylation at the secondary alcohol and exposure to potassium carbonate in methanol delivered *epi*-(C2'')-nocardioazine A (**37**). Unfortunately, attempts to correct the stereochemistry by double inversion strategies or oxidation/reduction sequences were unsuccessful.

Given the challenges encountered in attempting to epoxidize **34**, a revised strategy utilizing an early-stage epoxidation and diketopiperazine-forming macrocyclization was pursued (Scheme 5). Thus, 3a-allyl pyrroloindoline **23** was converted to allylic alcohol **39** in two steps. Sharpless asymmetric epoxidation delivered epoxy alcohol **40** in 10:1 dr,¹⁴ which was converted to mesylate **41**. Concomitantly, amine **43** was prepared from *endo*-pyrroloindoline **42** by Pd-catalyzed deallylation. After extensive optimization of the reaction parameters, it was found that treatment of amine **43** and mesylate **41** with catalytic TBAI and Hünig's base in acetonitrile at 90 °C delivers bis(pyrroloindoline) **44** in 74% yield. Exposure of **44** to excess LiOH resulted in saponification of the methyl esters and hydrolysis of the trifluoroacetamides to give bis(amino acid) **45**. We were pleased to find that subjection of **45** to PyBroP in DMF promoted intramolecular DKP formation to afford (+)-nocardioazine A (**2**). The optical rotation of synthetic **2** was determined to be the same sign and similar magnitude as that reported by Capon and coworkers in the original isolation paper.^{2b} As a result, we have revised Capon's assignment of the absolute stereochemistry of (+)-**2** to that shown throughout this manuscript, which is consistent with Ye and coworkers's reassignment of (+)-**3**.³ The synthesis of (+)-**2** requires nine linear steps and proceeds in 11% overall yield from 3-allylindole. In addition, these findings establish the viability of macrocyclization by intramolecular DKP formation.

In summary, the enantioselective total syntheses of the DKP-containing pyrroloindoline natural products (–)-lansai B (**1**), (+)-nocardioazine A (**2**), and (+)-nocardioazine B (**3**) were accomplished. These studies demonstrate the utility of enantioselective formal (3 + 2) cycloaddition reactions to prepare highly functionalized pyrroloindolines for applications in total synthesis. In addition, subtle changes in the relative stereochemistry and nitrogen substitution patterns of pyrroloindolines were shown to significantly influence the ability to prepare bis(pyrroloindolines) by DKP formation. Further investigations of **3** as an inhibitor of P-glycoprotein are ongoing in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- [1]. a) Shaw KTY, Utsuki T, Rogers J, Yu Q-S, Sambamurti K, Brossi A, Ge Y-W, Lahiri DK, Greig NH. *Proc. Natl. Acad. Sci. U.S.A.* 2001; 98:7605–7610. [PubMed: 11404470] b) Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. *Blood.* 2007; 109:2579–2588. [PubMed: 17090648]
- [2]. a) Tuntiwachwuttikul P, Taechowisan T, Wanbanjob A, Thadaniti S, Taylor WC. *Tetrahedron.* 2008; 64:7583–7586. b) Raju R, Piggott AM, Huang X, Capon RJ. *Org. Lett.* 2011; 13:2770–2773. [PubMed: 21513295]
- [3]. Wang M, Feng X, Cai L, Xu Z, Ye T. *Chem. Commun.* 2012; 48:4344–4346. This communication resulted in the reassignment of the absolute stereochemistry of nocardioazine B.
- [4]. a) Repka LM, Ni J, Reisman SE. *J. Am. Chem. Soc.* 2010; 132:14418–14420. [PubMed: 20873714] c) Repka LM, Reisman SE. *J. Org. Chem.* 2013; 78:12314. [PubMed: 24295135] Ni J, Wang H, Reisman SE. *Tetrahedron.* 2013; 69:5622–5633. [PubMed: 24039305] For a review of catalytic, asymmetric methods to prepare pyrroloindolines, see:
- [5]. Yang Y, Buchwald SL. *J. Am. Chem. Soc.* 2013; 135:10642–10645. [PubMed: 23837686] **L1** = dicyclohexyl(2-(2-methoxynaphthalen-1-yl)phenyl)phosphine, see Supporting Information for structure.
- [6]. King SB, Ganem B. *J. Am. Chem. Soc.* 1994; 116:562–570.
- [7]. Valeur E, Bradley M. *Chem. Soc. Rev.* 2009; 38:606. [PubMed: 19169468]
- [8]. Depew KM, Marsden SP, Zatorska D, Zatorski A, Bornmann WG, Danishefsky SJ. *J. Am. Chem. Soc.* 1999; 121:11953–11963.
- [9]. See Supporting Information.
- [10]. See Supporting Information for optimization experiments.
- [11]. Garro-Helion F, Merzouk A, Guibe F. *J. Org. Chem.* 1993; 58:6109–6113.
- [12]. Chatterjee AK, Sanders DP, Grubbs RH. *Org. Lett.* 2002; 4:1939–1942. [PubMed: 12027652]
- [13]. Eames J, Mitchell HJ, Nelson A, O'Brien P, Warren S, Wyatt P. *J. Chem. Soc., Perkin Trans. 1.* 1999:1095–1104.
- [14]. Gao Y, Klunder JM, Hanson RM, Masamune H, Ko SY, Sharpless KB. *J. Am. Chem. Soc.* 1987; 109:5765–5780.







Figure 1. Retrosynthetic analysis of (-)-lansai B (1), (+)-nocardiozine A (2), and (+)-nocardiozine B (3). TFA=trifluoroacetamido.

**Scheme 1.**


Synthesis of the pyrroloindoline fragments of (-)-lansai B (**1**). AcCl=acetyl chloride.

**Scheme 2.**


Synthesis of (-)-lansai B (1). BOP-Cl=bis(2-oxo-3-oxazolidinyl) phosphinic chloride, DIPEA=*N,N*-diisopropylethylamine

**Scheme 3.**

Synthesis of (+)-nocardiozine B (**3**). LiHMDS=lithium hexamethyl-disilazide, TfOH=trifluoromethane-sulfonic acid, dba=dibenzylideneacetone, DCE=dichloroethane, DMBA=1,3-dimethylbarbituric acid, dppb=1,4-bis(diphenylphosphino)butane

**Scheme 4.**

Synthesis of the nocardiozine A macrocycle. MsCl=methanesulfonyl chloride, TBAI=tetrabutylammonium iodide.

**Scheme 5.**

Synthesis of (+)-nocardiozine A (2). PyBroP= bromotripyrro-lidinophosphonium hexafluorophosphate, DMF=*N,N*-dimethylformamide.